Propanc Biopharma Highlights PRP Proenzyme Therapy Aimed At $3B+ Pancreatic Cancer Market With Grim 13% Survival Rate

Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology's most desperate battlegrounds with a grim 13% five-year survival rate.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:

- >85% tumor growth inhibition demonstrated in preclinical pancreatic models  

- Forces malignant cells to differentiate—attacking cancer at its root  

- Reduces fibrosis and resistance markers in the tumor microenvironment  

- Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity  

- Targets cancer stem cells to cut recurrence risk

Propanc is advancing PRP toward clinical development for advanced solid tumors, with pancreatic and ovarian cancers as initial priorities.